ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

March 12, 2007 13:35 ET

ART Advanced Research Technologies to Present Softscan at The Breast Course Symposium in Florida

MONTREAL, CANADA--(CCNMatthews - March 12, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce its participation as a Bronze Sponsor and exhibitor in the 2007 edition of The Breast Course, to be held at the Ocean Reef Club in Key Largo, Florida, from March 12-15, 2007.

The course is a multidisciplinary event aiming to present the best practices and state-of-the-art products to breast professionals.

"With Health Canada and CE Marking approval recently obtained for SoftScan®, we are very excited that many health providers present at this symposium will now be able to benefit from this innovative breast optical imaging system," said Sebastien Gignac, ART's President and CEO. "The Breast Course will once again be bringing together an international faculty of opinion leaders in breast cancer detection, intervention and therapy offering top-notch instruction to more than 120 participants from 16 countries," he added.

In addition, ART will be at the event as an exhibitor, and will present its SoftScan® breast imaging device designed to improve the diagnosis and treatment of breast cancer, at its booth located in the North Town Hall Ballroom of the Ocean Reef Club.

About SoftScan

The SoftScan optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow better characterization of breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. The device was created and developed by ART Advanced Research Technologies Inc.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the Management Proxy Circular of ART dated October 24, 2006, available on SEDAR (www.sedar.com) under the profile of "ART Advanced Research Technologies Inc. (old)" (ART's predecessor issuer).

Contact Information